Stockscreener 앱 받기
2.62
4.38%
-0.12
시간 외 거래:
2.62
Nkarta Inc 주식(NKTX)의 최신 뉴스
NKTX Q1 2026 Earnings: Narrower-than-Expected Loss and Promising Pipeline Updates Spark 12% Rally - newsline.com
Nkarta Shareholders Back Directors, Auditor and Annual Say-on-Pay - TipRanks
Nkarta (NKTX) investors approve directors, auditor and annual say-on-pay - Stock Titan
Nkarta (NASDAQ: NKTX) reports 37,000-share option grant tied to RA Capital - Stock Titan
Nkarta (NKTX) director awarded 37,000 stock options vesting in 2027 - Stock Titan
Nkarta (NKTX) director George Simeon awarded 37,000-share stock option grant - Stock Titan
Nkarta (NKTX) director receives stock options on 37,000 common shares - Stock Titan
Nkarta (NKTX) director granted 37,000 stock options for RA Capital funds - Stock Titan
Nkarta director granted options on 37,000 shares | NKTX Insider Trading - Stock Titan
Nkarta (NKTX) director awarded stock options for 37,000 shares at $2.46 - Stock Titan
Nkarta (NKTX) director Angela Thedinga awarded 37,000 stock options - Stock Titan
NKTX Q1 2026 Earnings: Narrower-Than-Expected Loss as Pre-Revenue Biotech Advances PipelineFree Cash Flow Trends - newsline.com
Nkarta Inc. (NKTX) Edges Lower: Assessing Support and Resistance in a Volatile Biotech MarketDefined Outcome ETF - newsline.com
NKTX stock up on upbeat regulatory update on lead autoimmune program - MSN
Nkarta Inc. (NKTX) Edges Higher on Above-Average Volume, Nears Key ResistanceDealer Positioning - newsline.com
NKTX Q1 2026 Earnings: Narrower-than-Expected Loss Amid Clinical ProgressTech Earnings Analysis - The Legal Advocate
NKTX Q1 2026 Earnings: Narrower-than-expected loss lifts sharesEarnings Quality Analysis - newsline.com
Nkarta Inc. (NKTX) Rallies 3.45% as Buyers Defend Key Support LevelSign of Strength - thelegaladvocate.com
Nkarta’s NK Cell Therapy Push Moves Into Outpatient Care - Finimize
Nkarta Inc. (NKTX) Advances 4.25% as Biotech Sector Momentum BuildsMESA MA - thelegaladvocate.com
Nkarta Inc. (NKTX) Q1 2026 Earnings: Narrower Loss Surprises as Pre-Revenue Biotech Advances Pipeline - The Legal Advocate
Nkarta Inc. (NKTX) Holds Steady at $3.03 as Market Awaits CatalystATR Stop - Newser
Nkarta (NKTX) Posts Record Q1 2026 — EPS $-0.37 Blows Past EstimatesRising Community Picks - newser.com
NEA (NKTX) drops below 5% ownership in latest Schedule 13D/A filing - Stock Titan
Nkarta Insider Stock Sellers Must Be Relieved As Market Cap Falls To US$201m - simplywall.st
Here's Why We're Not Too Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Situation - Yahoo Finance
Nkarta Price Target Maintained With a $11.00/Share by Needham - Moomoo
Nkarta, Inc. Stock 12‑Month Price Target Raised to $11.8, Implies 260% Upside - TradingView
Nkarta (NASDAQ:NKTX) Q1 2026 Narrower Loss Beats Estimates as Autoimmune Trial Advances - ChartMill
Nkarta (NASDAQ: NKTX) Q1 2026 loss narrows as cash reaches $266.7M - Stock Titan
Nkarta Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Nkarta, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Kyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial Results - Weekly Voice
Nkarta (NKTX) Q1 2026 results: NKX019 trial progress and cash runway into 2029 - Stock Titan
Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights - The Manila Times
FDA deal lets Nkarta test autoimmune cell therapy in community clinics - Stock Titan
TradingKey - TradingKey
How Nkarta (NKTX) performance compares to expectations (Momentum Fading) 2026-05-08Social Buzz - newser.com
Nkarta, Inc. (NASDAQ:NKTX) Given Average Rating of "Hold" by Analysts - MarketBeat
NKTX Q1'26 Earnings: revenue estimate is 0 USD - TradingView
NKTX Nkarta reports wider than expected Q4 2025 loss, shares fall nearly 3% on weak investor sentiment.AI Stock Signals - Newser
Nkarta (NASDAQ:NKTX) Stock Price Down 3.1%Here's Why - MarketBeat
[ARS] Nkarta, Inc. SEC Filing - Stock Titan
Executive pay, auditor and board elections on ballot at Nkarta (NKTX) 2026 virtual meeting - Stock Titan
NKTX (Nkarta Inc.) reports wider than expected Q4 2025 loss, shares jump nearly 16 percent on upbeat investor sentiment.Retail Trader Ideas - Cổng thông tin điện tử Tỉnh Sơn La
1.27%
1.43%
자본화:
|
볼륨(24시간):